anti-B4 blocked ricin immunoconjugate

Known as: anti-B4 blocked ricin, monoclonal antibody, Anti B4-BR, Anti-B4-bR 
An immunotoxin comprised of an anti-B4 (anti-CD19) murine monoclonal antibody linked to the modified plant-derived toxin blocked ricin. The antibody… (More)
National Institutes of Health

Related topics

Related topics

9 relations
ApoptosisB-LymphocytesCD19 AntigensRibosomes
(More)

Broader (3)

ImmunoconjugatesMonoclonal AntibodiesRicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2003
2003
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.
BACKGROUND Anti-B4-blocked ricin is an immunotoxin comprised of an anti-CD19 murine monoclonal antibody (B4) conjugated to… (More)
Is this relevant?
2001
2001
Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma.
Monoclonal antibodies, specific for antigens expressed on lymphoid malignancies, which have been conjugated to toxins such as… (More)
  • table 1
  • table 2
Is this relevant?
1998
1998
Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
Immunotoxins, composed of a monoclonal antibody conjugated to a protein toxin, mediate cell death through novel cytotoxic… (More)
Is this relevant?
1997
1997
Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
PURPOSE Immunotoxins could improve outcome in small-cell lung cancer (SCLC) by targeting tumor cells that are resistant to… (More)
Is this relevant?
1993
1993
Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
Anti-CD19 monoclonal antibody anti-B4 (IgG1) conjugated to the novel toxin-blocked ricin forms a potent immunotoxin, anti-B4… (More)
  • figure I
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Is this relevant?
1993
1993
Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma.
Anti-B-blocked ricin (anti-B4-bR) combines the specificity of the anti-B4 (CD19) monoclonal antibody with the protein toxin… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 4
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.
PURPOSE This phase I trial was undertaken to determine the maximum-tolerated dose (MTD) and dose-limiting toxicities (DLTs) of… (More)
Is this relevant?
Highly Cited
1992
Highly Cited
1992
Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion.
Anti-B4-blocked Ricin (Anti-B4-bR) is an immunotoxin comprised of the anti-B4 monoclonal antibody (MoAb) and the protein toxin… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
1992
1992
Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
Anti-B4-blocked ricin (Anti-B4-bR) is an immunotoxin comprised of the anti-B4 monoclonal antibody and the protein toxin, "blocked… (More)
  • figure I
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
1988
Highly Cited
1988
Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
A monoclonal anti-Thy-1.1 antibody (OX7) was coupled to either native or chemically deglycosylated ricin A-chain (dgA) using one… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • table 3
Is this relevant?